Previous 10 | Next 10 |
home / stock / dsnky / dsnky news
2023-10-31 10:15:00 ET Big pharmas have the resources to make big, multi-year moves that can reshape or even redefine their businesses. As you may know, Merck (NYSE: MRK) is one of the largest of the big pharmas, with a market capitalization of $262 billion, and it just made one of ...
2023-10-30 07:39:24 ET More on Deciphera Deciphera Pharmaceuticals Pipeline Is Underwhelming Deciphera Pharmaceuticals: Clawing Its Way Back Deciphera Pharmaceuticals, Inc. (DCPH) Q2 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Deciphe...
2023-10-26 09:00:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. A historically wide di...
2023-10-26 08:45:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. A historically wide di...
2023-10-26 07:05:54 ET More on Merck Merck & Co. Inc. (MRK) Merck & Co. Announced Collaboration with Daiichi Sankyo and ESMO Investor Event (Transcript) Merck Q3 2023 Earnings Preview: Keytruda LOE Continues To Dominate Narrative Merck: Right On Time ...
2023-10-23 09:02:58 ET Summary Daiichi Sankyo has entered into a collaboration with Merck for three antibody-drug conjugates, bringing in a significant upfront payment and potential milestone payments. The three drugs in development, targeting HER3, B7-H3, and CDH6, have shown pro...
2023-10-23 06:09:11 ET Summary Daiichi Sankyo is a Japanese pharmaceutical company known for its flagship products Lixiana and Enhertu. Enhertu is becoming a popular treatment for breast cancer, based on technology that is substituting chemotherapy. Long-term earnings outlook ...
2023-10-22 09:00:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. We have been surprised...
2023-10-20 11:12:54 ET More on Merck Merck: Right On Time Merck Vs. GSK: The Game-Changer Race In Pharma Excellence Merck: Still Fundamentally Undervalued Considering Keytruda's Prospects Merck study shows Keytruda can help lower death risk from cervical canc...
2023-10-19 23:52:31 ET More on Daiichi, Merck, etc. Merck: Right On Time Merck Vs. GSK: The Game-Changer Race In Pharma Excellence Merck: Still Fundamentally Undervalued Considering Keytruda's Prospects AstraZeneca drops after Phase 3 data for lung cancer the...
News, Short Squeeze, Breakout and More Instantly...
Daiichi Sankyo Co Ltd Sponsored ADR Level 1 Company Name:
DSNKY Stock Symbol:
OTCMKTS Market:
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig PR Newswire Phase 3 trial evaluating rilvegostomig as monotherapy and in combination with AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan in ...
2023-10-31 10:15:00 ET Big pharmas have the resources to make big, multi-year moves that can reshape or even redefine their businesses. As you may know, Merck (NYSE: MRK) is one of the largest of the big pharmas, with a market capitalization of $262 billion, and it just made one of ...
Astellas, Eisai, Daiichi Sankyo and Takeda Agree to Collaborate to Reduce Environmental Burden in the Field of Pharmaceutical Packaging PR Newswire TOKYO and OSAKA, Japan , Dec. 21, 2022 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO:...